| answer text |
<p>As the world grapples with the burden of the COVID-19 pandemic, the UK has been
clear that equitable global distribution of a vaccine will be the best defence, enable
collective recovery and reduce the risk of repeat outbreaks.</p><p>The UK is supporting
the COVAX Advance Market Commitment (AMC) which aims to ensure access to COVID-19
vaccines in developing countries. At the Global Vaccine Summit, which the Prime Minister
hosted on 4<sup>th</sup> June, the UK repurposed £48 million to the AMC. At the Summit,
AstraZeneca also announced a commitment of 300 million doses of the University of
Oxford candidate vaccine to the COVAX facility.</p><p>The COVAX AMC will incentivise
vaccine manufacturers to produce sufficient quantities of eventual COVID-19 vaccines
and to ensure access for the world’s poorest countries. Gavi, the Vaccine Alliance,
the Coalition for Epidemic Preparedness Innovations, and the World Health Organization
are working together to ensure that the vaccines are affordable and available equitably.
Through the deal with AstraZeneca, the University of Oxford COVID-19 vaccine candidate
have been committed towards the COVAX Facility.</p>
|
|
